CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 72 enrolled
Drug / intervention
Saxagliptindrug
Likely dose
Saxagliptin 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02182895
NCT02182895Phase 4Completed
CompareCT.gov

Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

Brigham and Women's Hospital·interventional·Posted Jul 8, 2014·Updated Jun 23, 2017

In Brief

A Phase 4 clinical trial evaluating Saxagliptin for Diabetes Mellitus. Completed, enrolled 72 participants across 1 site.

Detailed Summary

The purpose of this research study is to test the safety and efficacy of a drug called saxagliptin (Onglyza) for treatment of type 2 diabetes in non-critically ill hospitalized patients who have an HbA1c of 7.5 or lower, on 1 or no non-insulin agent at home, or an HbA1c ≤7.0% on ≤ 2 non-insulin agents at home.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 8, 2014
Enrollment StartJul 1, 2014
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 12.0 years ago

Interventions

Saxagliptindrug

2.5-5 mg daily